Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial.

Hata A, Inoue F, Hamamoto Y, Yamasaki M, Fujikawa J, Kawahara H, Kawasaki Y, Honjo S, Koshiyama H, Moriishi E, Mori Y, Ohkubo T.

Diabet Med. 2016 Aug;33(8):1094-101. doi: 10.1111/dme.13038. Epub 2015 Dec 29.

PMID:
26605507
2.

Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in subjects with diabetes mellitus.

Hata A, Inoue F, Yamasaki M, Fujikawa J, Kawasaki Y, Hamamoto Y, Honjo S, Moriishi E, Mori Y, Koshiyama H.

J Infect. 2013 Sep;67(3):215-9. doi: 10.1016/j.jinf.2013.04.010. Epub 2013 Apr 18.

PMID:
23603250
3.

The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.

Winthrop KL, Wouters AG, Choy EH, Soma K, Hodge JA, Nduaka CI, Biswas P, Needle E, Passador S, Mojcik CF, Rigby WF.

Arthritis Rheumatol. 2017 Oct;69(10):1969-1977. doi: 10.1002/art.40187. Epub 2017 Sep 6.

4.

Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Eberhardson M, Hall S, Papp KA, Sterling TM, Stek JE, Pang L, Zhao Y, Parrino J, Popmihajlov Z.

Clin Infect Dis. 2017 Oct 1;65(7):1174-1182. doi: 10.1093/cid/cix484.

PMID:
29126292
5.

Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.

Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, Chan IS, Williams H, Harbecke R, Marchese R, Straus SE, Gershon A, Weinberg A; Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators.

J Infect Dis. 2008 Mar 15;197(6):825-35. doi: 10.1086/528696.

6.

A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.

Strezova A, Godeaux O, Aggarwal N, Leroux-Roels G, Lopez-Fauqued M, Van Damme P, Vanden Abeele C, Vastiau I, Heineman TC, Lal H.

Vaccine. 2017 Dec 4;35(48 Pt B):6700-6706. doi: 10.1016/j.vaccine.2017.10.017. Epub 2017 Oct 24.

7.

Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.

Diez-Domingo J, Weinke T, Garcia de Lomas J, Meyer CU, Bertrand I, Eymin C, Thomas S, Sadorge C.

Vaccine. 2015 Feb 4;33(6):789-95. doi: 10.1016/j.vaccine.2014.12.024. Epub 2014 Dec 30.

8.

Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial.

Trannoy E, Berger R, Holländer G, Bailleux F, Heimendinger P, Vuillier D, Creusvaux H.

Vaccine. 2000 Feb 25;18(16):1700-6.

PMID:
10689152
9.

Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.

Vermeulen JN, Lange JM, Tyring SK, Peters PH, Nunez M, Poland G, Levin MJ, Freeman C, Chalikonda I, Li J, Smith JG, Caulfield MJ, Stek JE, Chan IS, Vessey R, Schödel FP, Annunziato PW, Schlienger K, Silber JL.

Vaccine. 2012 Jan 20;30(5):904-10. doi: 10.1016/j.vaccine.2011.11.096. Epub 2011 Dec 7.

PMID:
22154769
10.

Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.

Levin MJ, Schmader KE, Pang L, Williams-Diaz A, Zerbe G, Canniff J, Johnson MJ, Caldas Y, Cho A, Lang N, Su SC, Parrino J, Popmihajlov Z, Weinberg A.

J Infect Dis. 2016 Jan 1;213(1):14-22. doi: 10.1093/infdis/jiv480. Epub 2015 Oct 9.

PMID:
26452397
11.

Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.

Sullivan NL, Reuter-Monslow MA, Sei J, Durr E, Davis CW, Chang C, McCausland M, Wieland A, Krah D, Rouphael N, Mehta AK, Mulligan MJ, Pulendran B, Ahmed R, Vora KA.

J Virol. 2018 Jun 29;92(14). pii: e00269-18. doi: 10.1128/JVI.00269-18. Print 2018 Jul 15.

PMID:
29743372
12.

Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults.

Macaladad N, Marcano T, Guzman M, Moya J, Jurado F, Thompson M, Meechan C, Li D, Schlienger K, Chan I, Sadoff J, Schödel F, Silber JL.

Vaccine. 2007 Mar 1;25(11):2139-44. Epub 2006 Nov 27.

PMID:
17250932
13.

Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.

Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Schödel F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ; US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators.

J Infect Dis. 2009 Oct 1;200(7):1068-77. doi: 10.1086/605611.

14.

A community-based survey of varicella-zoster virus-specific immune responses in the elderly.

Tang H, Moriishi E, Okamoto S, Okuno Y, Iso H, Asada H, Yamanishi K, Mori Y; Shozu Herpes Zoster Study group.

J Clin Virol. 2012 Sep;55(1):46-50. Epub 2012 Jul 6.

PMID:
22771002
15.

Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.

Grupping K, Campora L, Douha M, Heineman TC, Klein NP, Lal H, Peterson J, Vastiau I, Oostvogels L.

J Infect Dis. 2017 Dec 12;216(11):1343-1351. doi: 10.1093/infdis/jix482.

16.

Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications.

Irwin MR, Levin MJ, Laudenslager ML, Olmstead R, Lucko A, Lang N, Carrillo C, Stanley HA, Caulfield MJ, Weinberg A, Chan IS, Clair J, Smith JG, Marchese RD, Williams HM, Beck DJ, McCook PT, Zhang JH, Johnson G, Oxman MN.

Clin Infect Dis. 2013 Apr;56(8):1085-93. doi: 10.1093/cid/cis1208. Epub 2013 Feb 13.

17.

Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.

Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE, Stek JE, Schlienger K, Chan IS, Silber JL.

Vaccine. 2010 Jun 7;28(25):4204-9. doi: 10.1016/j.vaccine.2010.04.003. Epub 2010 Apr 21.

PMID:
20416263
18.

Vaccines for preventing herpes zoster in older adults.

Gagliardi AM, Andriolo BN, Torloni MR, Soares BG.

Cochrane Database Syst Rev. 2016 Mar 3;3:CD008858. doi: 10.1002/14651858.CD008858.pub3. Review.

PMID:
26937872
19.

Vaccines for preventing herpes zoster in older adults.

Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD008858. doi: 10.1002/14651858.CD008858.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;3:CD008858.

PMID:
23076951
20.

Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.

Levin MJ, Buchwald UK, Gardner J, Martin J, Stek JE, Brown E, Popmihajlov Z.

Vaccine. 2018 Jan 2;36(1):179-185. doi: 10.1016/j.vaccine.2017.08.029. Epub 2017 Aug 19.

Supplemental Content

Support Center